Blog

Future Fifty: joining forces to drive forward positive change

We are immensely excited and proud to have been selected for Tech Nation's 2020 Future Fifty cohort, alongside 28 fellow UK tech trailblazers.

It’s been an honour witnessing the impressive growth of the UK tech scene over the past decade. Before joining Benevolent in 2018, I spent five years helping the Government harness the potential of technology: maximising the growth of the digital economy and serving as the UK’s first Minister for Internet Security and Safety. In the years since thousands of fast-growth startups have flourished in Britain, each founded with the hope that our world can be improved through technology. It is gratifying to see that so many fellow members of this year's Future Fifty cohort are inspired and committed to the dream of ‘what can be’, and are channelling this into innovations that fundamentally change things for the better.

Tech Nation’s Future Fifty was founded with the purpose of bringing together the country’s most successful tech businesses to build a powerful network of peers. With the help of the tech community, the programme supports companies in achieving their global ambitions, creating jobs and opportunities across the UK, and inspiring the next generation of tech entrepreneurs, founders and businesses. Community and knowledge sharing helped establish the UK as one of the leading locations to start, nurture and grow or tech-enabled disruptive businesses, with a number of high profile success stories listing on the LSE.

In these challenging times, we have seen the global scientific community mobilise to respond to the deadly disease ravaging our planet, and have once again witnessed how community serves as a powerful vehicle for transformation and hope. Finally, as UK tech journeys into a new phase in a post-Brexit world, it is more important than ever that we join forces with like-minded industry experts to drive forward towards a more purposeful future.

I am inspired by the uncompromising determination and passion of the talented team we have assembled here at Benevolent.  We are united by our mission to push the boundaries of technology and to use AI and machine learning to develop more effective medicines for patients in areas of significant unmet need. Experts from diverse technology and scientific disciplines such as machine learning, drug discovery and engineering work together towards a common goal: a future in which no disease goes untreated. Having Future Fifty by our side for the journey ahead will undoubtedly help us further deliver against this vision.

The saying goes that the whole is greater than the sum of its parts. This is no doubt true of the UK tech scene: together, we make up the number-three tech startup ecosystem in the world. Together, we have secured our place at the heart of the biggest story of 21st-century growth and promise. Together, we are working on solutions to pressing global challenges that will impact quality of life and improve society for all.

Joanna Shields, CEO

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021